Methicillin-Resistant Staphylococcus AureuS Clinical Trial
Official title:
Population Pharmacokinetics of Linezolid in Intensive Care Units Patients Treated for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
Linezolid is the first of a new class of antibacterial drugs, the oxazolidinones. It has a
specific inhibitory activity against Gram positive bacteria, including methicillin-resistant
Staphylococcus aureus (MRSA).
Dosage of 600 mg discontinuous administration twice a day was about studies in safety
volunteers. The intensive care units patients, with mechanical ventilation, and with severe
sepsis, represent highly heterogeneous population responsible of hight variability in
pharmacokinetics parameters (augmentation in total volume of distribution, modification in
glomerular filtration) wich can lead to antibiotic inefficacy.
In a first time, this study describe the pharmacokinetics of Linezolid in intensive care
units patients with severe MRSA infection. The aim of this study is to define and validate a
population pharmacokinetic model including the influence of patients' characteristic on the
pharmacokinetics of Linezolid.
The demographic, clinical and biological parameters are collected. Patients receive
Linezolid as 600 mg twice a day during an administration of 60 minutes.
Blood sampling are collected on the second day after beginning of treatment at the following
time : H1, H2, H3, H6 and H12.
The population pharmacokinétics analysis will be carried out using Monolix, a software for
the analysis of nonlinear mixed effects models.
;
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05529173 -
Povidone-Iodine for Nasal Decolonization
|
Phase 4 | |
| Completed |
NCT00980980 -
Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)
|
N/A | |
| Recruiting |
NCT03412500 -
Vancomycin Dosage Adjustment for MRSA Infections
|
Phase 4 | |
| Recruiting |
NCT02566928 -
Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence
|
Phase 4 | |
| Terminated |
NCT01196169 -
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty
|
Phase 4 | |
| Completed |
NCT00996112 -
Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections
|
N/A | |
| Not yet recruiting |
NCT00773799 -
Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community
|
N/A | |
| Not yet recruiting |
NCT00773864 -
Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community-Healthcare Workers
|
N/A | |
| Completed |
NCT01350479 -
Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers
|
N/A | |
| Recruiting |
NCT03637400 -
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment
|
Phase 2 | |
| Withdrawn |
NCT00856089 -
Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
|
Phase 4 | |
| Recruiting |
NCT04171817 -
Animal-Assisted Visitation Program Chlorhexidine Trial
|
Phase 4 | |
| Completed |
NCT00324922 -
Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis
|
Phase 3 | |
| Completed |
NCT02814916 -
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
|
Phase 3 | |
| Withdrawn |
NCT00713674 -
Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx
|
N/A | |
| Not yet recruiting |
NCT05632315 -
PMT for MDRO Decolonization
|
Phase 2 | |
| Not yet recruiting |
NCT01356472 -
Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia
|
Phase 4 | |
| Completed |
NCT03886623 -
A Systematic Oral Care Program in Post-Mechanically Ventilated, Post-Intensive Care Patients
|
N/A | |
| Completed |
NCT01141101 -
Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus
|
N/A | |
| Completed |
NCT01138462 -
Control of MRSA in Nursing Homes: Decolonization vs Standard Precautions
|
N/A |